Prothena Corp PLC (PRTA)
13.56
-0.18 -1.31%
NASDAQ
Jan 20, 16:59
USD
Prothena Return on Equity
View 4,000+ financial data types
Browse...
Historical Return on Equity Data
View and export this data going back to 2013.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Sept. 30, 2020 | Upgrade |
June 30, 2020 | Upgrade |
March 31, 2020 | Upgrade |
Dec. 31, 2019 | Upgrade |
Sept. 30, 2019 | Upgrade |
June 30, 2019 | Upgrade |
March 31, 2019 | Upgrade |
Dec. 31, 2018 | Upgrade |
Sept. 30, 2018 | Upgrade |
June 30, 2018 | Upgrade |
March 31, 2018 | Upgrade |
Dec. 31, 2017 | Upgrade |
Sept. 30, 2017 | Upgrade |
June 30, 2017 | Upgrade |
March 31, 2017 | Upgrade |
Dec. 31, 2016 | Upgrade |
Sept. 30, 2016 | Upgrade |
June 30, 2016 | Upgrade |
March 31, 2016 | Upgrade |
Dec. 31, 2015 | Upgrade |
Sept. 30, 2015 | Upgrade |
June 30, 2015 | Upgrade |
March 31, 2015 | Upgrade |
Dec. 31, 2014 | Upgrade |
Sept. 30, 2014 | Upgrade |
June 30, 2014 | Upgrade |
March 31, 2014 | Upgrade |
Dec. 31, 2013 | Upgrade |
Sept. 30, 2013 | Upgrade |
June 30, 2013 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Return on Equity for PRTA
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Advertisement
Return on Equity (ROE) Definition
Return on Equity measures Net Income / Average Shareholder's Equity. This metric is important because it gives an idea of how efficiently a business is being run. ROE can vary for different sectors and industries depending on the financial statement structures.
Return on Equity Benchmarks
Alkermes PLC | Upgrade |
Amarin Corp PLC | Upgrade |
Jazz Pharmaceuticals PLC | Upgrade |
Return on Equity Range, Past 5 Years
Minimum | Upgrade | Jun 2018 |
Maximum | Upgrade | Mar 2016 |
Average | Upgrade |
Return on Equity Related Metrics
Return on Assets | Upgrade |
Return on Invested Capital | Upgrade |
Profit Margin (Quarterly) | Upgrade |
Operating Margin (Quarterly) | Upgrade |
Return on Net Operating Assets | Upgrade |
News
Sector Update: Consumer Staples, Discretionary Stocks Closing Gap Slightly Just Ahead of Tuesday's Close
MT Newswires 01/12 15:54 ET
MT Newswires 01/12 15:54 ET
--Analyst Actions: Oppenheimer Adjusts Prothena's Price Target to $25 From $20, Maintains Outperform Rating
MT Newswires 12/10 11:09 ET
MT Newswires 12/10 11:09 ET
Prothena Reports Positive Data From Phase 1 Study of PRX004 to Treat ATTR Amyloidosis; Shares Surge 25% Pre-Bell
MT Newswires 12/09 08:56 ET
MT Newswires 12/09 08:56 ET
Prothena's immunotherapy show slowing neuropathy progression in long-term amyloidosis study
SA Breaking News 12/09 08:38 ET
SA Breaking News 12/09 08:38 ET
Analyst Actions: HC Wainwright Starts Prothena at Buy With $22 Price Target
MT Newswires 12/07 08:00 ET
MT Newswires 12/07 08:00 ET
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire 12/04 16:05 ET
Globe Newswire 12/04 16:05 ET
Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Yahoo 11/16 02:56 ET
Yahoo 11/16 02:56 ET
--Analyst Actions: Oppenheimer Adjusts Prothena PT to $20 From $18, Maintains Outperform Rating
MT Newswires 11/05 12:23 ET
MT Newswires 11/05 12:23 ET
-- Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q3 Revenue $157,000, vs. Street Est of $0.193M
MT Newswires 11/04 16:41 ET
MT Newswires 11/04 16:41 ET
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
Globe Newswire 11/04 16:05 ET
Globe Newswire 11/04 16:05 ET
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Globe Newswire 11/04 08:30 ET
Globe Newswire 11/04 08:30 ET
Advertisement